Merck Expands EGFR Targeted Portfolio

Acquiring Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 From Symphogen

07-Sep-2012 - Merck announced that an exclusive worldwide license agreement was signed with Symphogen A/S for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR). Sym004 is currently being evaluated in a Phase I/II trial for the treatment of patients with advanced ...

Swedish Orphan Biovitrum returns development rights to Sym001 to Symphogen

30-Dec-2010 - Swedish Orphan Biovitrum announced that it has returned full development rights to Symphogen, co-developer of Sym001, for ITP (Immune Thrombocytopenic Purpura) treatment and for HDN (Hemolytic Disease in Newborn) prophylaxis, for strategic reasons. Sym001 is currently in clinical phase II for ...

Symphogen and Swedish Orphan Biovitrum receive U.S. orphan drug designation for Rozrolimupab in ITP

08-Oct-2010 - Symphogen and Swedish Orphan Biovitrum announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to rozrolimupab (Sym001) for the treatment of primary Immune Thrombocytopenia (ITP). ITP is an autoimmune bleeding disorder characterized by abnormally ...

Biovitrum and Symphogen Report Positive Clinical Results in Novel Rh-immunization Prevention Project

24-Nov-2008 - Biovitrum AB and Symphogen A/S have completed the first part of a clinical proof of mechanism study of the recombinant human polyclonal antibody product Sym001 for future prevention of Hemolytic Disease of the Newborn (HDN) that can occur in RhD-negative mothers carrying a RhD-positive fetus. ...

CMC Biologics A/S Announce Manufacturing Agreement with Symphogen A/S

12-Aug-2008 - CMC Biologics A/S announced that it has entered into an agreement with Symphogen A/S for process development and cGMP manufacture of an undisclosed polyclonal antibody product candidate from Symphogen's development pipeline. Terms of the agreement were not disclosed. "We are pleased to establish ...

Biovitrum and Symphogen Initiates a Second Clinical study with a Novel Treatment of Hemolytic Diseases

21-Apr-2008 - Biovitrum AB and Symphogen A/Sannounced the initiation of a clinical proof of mechanism study to demonstrate the ability of Sym001 (RhD polyclonal antibody) to clear RhD-positive red blood cells from the circulation of RhD-negative healthy volunteers. Clearance of red blood cells by RhD ...

Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial with Recombinant Polyclonal Antibody

07-Feb-2008 - Biovitrum and Symphogen announced the completion of a phase I clinical trial to test the safety and tolerability of Sym001 in healthy volunteers. The results from the dose-escalation, placebo-controlled study show that Sym001 is well tolerated. Sym001 is a recombinant, polyclonal antibody ...

Symphogen A/S and Biovitrum AB enter into agreement for anti-Rhesus D antibodies

03-Feb-2006 - Symphogen A/S and Biovitrum AB have entered into a co-development and commercialization agreement for Sym001, Symphogen's lead product. Sym001 is a combination of 25 different recombinant anti-Rhesus D antibodies for the treatment of both Idiopathic Thrombocytopenic Purpura (ITP) and Hemolytic ...

Symphogen attracts new usd 25 million investment

10-Jan-2006 - Symphogen A/S announced the initial closing of a USD 25 million Series D financing at a premium to the last financing round. The financing will be used to carry out clinical trials of Symphogen's first product, anti-RhD for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and engage in ...

Symphogen and Cambridge Antibody Technology sign patent licensing agreement

30-Aug-2005 - Symphogen A/S announced that it has entered into a patent license agreement with Cambridge Antibody Technology. Under the terms of the agreement, Symphogen receives a license to use CAT's antibody phage display patents for research purposes and to develop and commercialize a number of therapeutic ...